Cardiometabolic Health: Current Developments

A special issue of Medical Sciences (ISSN 2076-3271). This special issue belongs to the section "Cardiovascular Disease".

Deadline for manuscript submissions: closed (31 December 2018) | Viewed by 6491

Special Issue Editors


E-Mail Website
Guest Editor
Medical Writer & Editorial Director, Cardiometabolic Health Congress, Boca Raton, FL, USA
Interests: Type 2 Diabetes; Obesity; Nutrition; Preventive Cardiology; Dyslipidemia; Atherosclerosis; Hypertension; Heart Failure
Special Issues, Collections and Topics in MDPI journals

E-Mail
Guest Editor
Lipid and Atherosclerosis Fellow, Baylor College of Medicine, Houston, TX, USA
Interests: precision medicine; preventative cardiology; atherosclerosis; lipidology; cardiometabolics

Special Issue Information

Dear Colleagues,

This Special Issue will contain selected papers presented at the 13th Annual Cardiometabolic Health Congress, which will take place 24–27 October 2018 in Boston, MA, USA. Full details about the conference can be found at: https://www.cardiometabolichealth.org/2018/boston-13th-annual.html. Only papers to be presented at the conference as poster presentations will be considered for publication in this Special Issue. As part of the submission process, it is required to state in your cover letter to the journal both the title and number of your abstract to be presented at the 13th Annual Cardiometabolic Health Congress.

The Special Issue will highlight new developments in the field of cardiometabolic health, including dyslipidemia, type 2 diabetes, obesity, cardiovascular risk reduction, weight management, hypertension, and more. As the global cardiometabolic disease epidemic grows, clinicians face a rapidly expanding and aging patient population, leaving them with an urgent need for access to evidence-based research. As an extension of the Cardiometabolic Health Congress, the largest US-based multidisciplinary conference focused solely on the prevention and management of cardiometabolic disease, this Special Issue will emphasize the complexities, challenges, and advancements in this field. It aims to give clinicians an additional platform to access articles that represent new updates in cardiometabolic health, and contributions will reflect the cross-disciplinary nature of the field.

Dr. Shpetim Karandrea
Dr. Xiaoming Jia
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medical Sciences is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiometabolic
  • type 2 diabetes
  • dyslipidemia
  • cardiovascular disease
  • atherosclerosis
  • obesity
  • hypertension
  • heart failure

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Other

10 pages, 449 KiB  
Article
Assessment of Cardiovascular Disease Risk and Therapeutic Patterns among Urban Black Rheumatoid Arthritis Patients
by Isabel M. McFarlane, Su Yien Zhaz Leon, Manjeet S. Bhamra, Aaliya Burza, Stephen Anthony Waite, Milena Rodriguez Alvarez, Kristaq Koci, Nicholas Taklalsingh, Ian Kaplan, Joshy Pathiparampil, Naureen Kabani, Elsie Watler, Cristina S. Sorrento, Mosab Frefer, Vytas Vaitkus, Jason Green, Keron Matthew, Fray Arroyo-Mercado, Helen Lyo, Faisal Soliman, Randolph A. Sanchez, Felix M. Reyes, David J. Ozeri, Veena Dronamraju, Michael Trevisonno, Christon Grant, Guerrier Clerger, Khabbab Amin, Latoya Freeman, Makeda Dawkins, Diana Lenis Lopez, Jonathan Smerling, Irfan Gondal, Elaine Dellinger, Karen Paltoo, Hina Bhat and Srinivas Kollaadd Show full author list remove Hide full author list
Med. Sci. 2019, 7(2), 31; https://doi.org/10.3390/medsci7020031 - 20 Feb 2019
Cited by 3 | Viewed by 3989
Abstract
Rheumatoid arthritis (RA) patients have nearly twice the risk of cardiovascular disease (CVD) compared to the general population. We aimed to assess, in a predominantly Black population, the prevalence of traditional and RA-specific CVD risk factors and therapeutic patterns. Utilizing ICD codes, we [...] Read more.
Rheumatoid arthritis (RA) patients have nearly twice the risk of cardiovascular disease (CVD) compared to the general population. We aimed to assess, in a predominantly Black population, the prevalence of traditional and RA-specific CVD risk factors and therapeutic patterns. Utilizing ICD codes, we identified 503 RA patients ≥18 years old who were seen from 2010 to 2017. Of them, 88.5% were Black, 87.9% were women and 29.4% were smokers. CVD risk factors (obesity, diabetes, hypertension, dyslipidemia) were higher than in previously reported White RA cohorts. Eighty-seven percent of the patients had at least one traditional CVD risk factor, 37% had three or more traditional CVD risk factors and 58% had RA-specific risk factors (seropositive RA, >10 years of disease, joint erosions, elevated inflammatory markers, extra-articular disease, body mass index (BMI) < 20). CV outcomes (coronary artery disease/myocardial infarction, heart failure, atrial fibrillation and stroke) were comparable to published reports. Higher steroid use, which increases CVD risk, and lesser utilization of biologics (decrease CV risk) were also observed. Our Black RA cohort had higher rates of traditional CVD risk factors, in addition to chronic inflammation from aggressive RA, which places our patients at a higher risk for CVD outcomes, calling for revised risk stratification strategies and effective interventions to address comorbidities in this vulnerable population. Full article
(This article belongs to the Special Issue Cardiometabolic Health: Current Developments)
Show Figures

Figure 1

Other

Jump to: Research

12 pages, 235 KiB  
Meeting Report
Report from the Scientific Poster Session at the 13th Annual Cardiometabolic Health Congress in Boston, USA, 24–27 October 2018
by Organizing Committee CMHC 2018
Med. Sci. 2018, 6(4), 111; https://doi.org/10.3390/medsci6040111 - 30 Nov 2018
Viewed by 2118
Abstract
More than one third of the population has at least one cardiometabolic risk factor-dyslipidemia, cardiovascular disease (CVD), hypertension, diabetes, and/or obesity. [...] Full article
(This article belongs to the Special Issue Cardiometabolic Health: Current Developments)
Back to TopTop